HCV infection: pathogenesis, clinical manifestations and therapy.
暂无分享,去创建一个
I. Olivieri | D. Vergani | G. Mieli-Vergani | D. Roccatello | A. Antonelli | F. Atzeni | M. Galeazzi | M. Puoti | C. Ferri | P. Sarzi-Puttini | D. Manno | C. Giannitti | C. Palazzi | E. Menegatti | P. Sarzi‐Puttini
[1] S. Pileri,et al. B-cells and mixed cryoglobulinemia. , 2007, Autoimmunity reviews.
[2] M. Veneziano,et al. Efficacy of low-dose rituximab for mixed cryoglobulinemia. , 2007, Clinical immunology.
[3] S. Pileri,et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[4] N. Lai,et al. Comparison of anti-agalactosyl IgG antibodies, rheumatoid factors, and anti-cyclic citrullinated peptide antibodies in the differential diagnosis of rheumatoid arthritis and its mimics. , 2007, Clinical and experimental rheumatology.
[5] M. Galeazzi,et al. Safety of Cyclosporin A in HCV‐Infected Patients , 2007, Annals of the New York Academy of Sciences.
[6] E. Ferrannini,et al. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. , 2007, Thyroid : official journal of the American Thyroid Association.
[7] M. Galeazzi,et al. Combination therapy with cyclosporine A and anti-TNF-α agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection , 2007, Clinical Rheumatology.
[8] C. Ferri,et al. Hepatitis C virus-related lymphoproliferative disorders: an overview. , 2007, World journal of gastroenterology.
[9] R. Simó. Glucose Abnormalities in Patients With Hepatitis C Virus Infection: Epidemiology and Pathogenesis , 2006, Diabetes Care.
[10] S. Aslanidis,et al. Inhibition of TNFα does not induce viral reactivation in patients with chronic hepatitis C infection: two cases , 2006, Clinical Rheumatology.
[11] M. Galeazzi,et al. Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients. , 2006, Autoimmunity reviews.
[12] M. Rotondi,et al. Thyroid disorders in chronic hepatitis C virus infection. , 2006, Thyroid : official journal of the American Thyroid Association.
[13] L. Quartuccio,et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. , 2006, Rheumatology.
[14] M. Berenguer,et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV‐infected liver transplant recipients , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[15] M. Hussain,et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. , 2006, Gastroenterology.
[16] S. S. Franceschini,et al. Interferon-γ-Inducible α-Chemokine CXCL10 Involvement in Graves’ Ophthalmopathy: Modulation by Peroxisome Proliferator-Activated Receptor-γ Agonists , 2006 .
[17] L. Rostaing,et al. Rituximab Therapy for De Novo Mixed Cryoglobulinemia in Renal Transplant Patients , 2005, Transplantation.
[18] E. Ferrannini,et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. , 2005, Diabetes care.
[19] F. Zoulim,et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. , 2005, Rheumatology.
[20] A. Cerny,et al. Hepatitis C virus and the immune system: a concise review , 2005, Reviews in medical virology.
[21] D. Vergani,et al. Susceptibility to thyroid disorders in hepatitis C. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[22] S. Levy,et al. The tetraspanin web modulates immune-signalling complexes , 2005, Nature Reviews Immunology.
[23] G. Mazzucco,et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[24] P. Simmonds,et al. Genetic diversity and evolution of hepatitis C virus--15 years on. , 2004, The Journal of general virology.
[25] J. Reveille,et al. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. , 2004, Arthritis and rheumatism.
[26] D. Vassilopoulos,et al. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection , 2004, Annals of the rheumatic diseases.
[27] E. Ferrannini,et al. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. , 2004, QJM : monthly journal of the Association of Physicians.
[28] E. Ferrannini,et al. Thyroid disorders in chronic hepatitis C. , 2004, The American journal of medicine.
[29] J. Naschitz,et al. The case for hepatitis C arthritis. , 2004, Seminars in arthritis and rheumatism.
[30] D. Vergani,et al. Multiple Viral/Self Immunological Cross-Reactivity in Liver Kidney Microsomal Antibody Positive Hepatitis C Virus-Infected Patients is Associated with the Possession of HLA B51 , 2004, International journal of immunopathology and pharmacology.
[31] M. Weinblatt,et al. Infections and anti–tumor necrosis factor α therapy , 2003 .
[32] M. Wener,et al. Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection , 2003, Annals of the rheumatic diseases.
[33] R. Barale,et al. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. , 2003, Rheumatology.
[34] G. Mazzucco,et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. , 2003, Kidney international.
[35] Felicia A Tucci,et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. , 2003, Blood.
[36] R. Fanin,et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. , 2003, Blood.
[37] I. Olivieri,et al. Hepatitis C virus and arthritis. , 2003, Rheumatic diseases clinics of North America.
[38] J. Hoofnagle. Course and outcome of hepatitis C , 2002, Hepatology.
[39] C. Ferri,et al. Erectile dysfunction and hepatitis C virus infection. , 2002, JAMA.
[40] R. Fanin,et al. Rituximab for the treatment of type II mixed cryoglobulinemia. , 2002, Arthritis and rheumatism.
[41] S. Bombardieri,et al. Treatment of chronic hepatitis C infection with cryoglobulinemia , 2002, Current opinion in rheumatology.
[42] C. Tiribelli,et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort , 1999, Gut.
[43] M. Houghton,et al. Binding of hepatitis C virus to CD81. , 1998, Science.
[44] M. Manns,et al. [Extrahepatic manifestations of hepatitis C infection]. , 1998, Zeitschrift fur Gastroenterologie.
[45] R. Dickson. Clinical manifestations of hepatitis C. , 1997, Clinics in liver disease.
[46] A. Lazzarin,et al. Impaired hepatosplenic elimination of circulating cryoglobulins in patients with essential mixed cryoglobulinaemia and hepatitis C virus (HCV) infection. , 1997, Clinical and experimental immunology.
[47] M. Clementi,et al. Low hepatitis C viremia levels in patients with anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis. , 1996, Journal of hepatology.
[48] G. D'Amico,et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. , 1995, Kidney international.
[49] K. Sullivan,et al. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. , 1991, The Journal of clinical investigation.
[50] F. Zoulim,et al. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. , 2007, Rheumatology.
[51] A. Amoroso,et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[52] I. Olivieri,et al. Difficulties in the differential diagnosis between primitive rheumatic diseases and hepatitis C virus-related disorders. , 2005, Clinical and experimental rheumatology.
[53] A. Iagnocco,et al. Joint sonography in asymptomatic patients with HCV correlated hepatitis. , 2004, Clinical and experimental rheumatology.
[54] M. Weinblatt,et al. Infections and anti-tumor necrosis factor alpha therapy. , 2003, Arthritis and rheumatism.
[55] J. Goedert. Infectious causes of cancer: targets for intervention. , 2000 .
[56] P. Cacoub,et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. , 1999, Arthritis and rheumatism.
[57] M. Baccarani,et al. Rituximab for the treatment of type II mixed cryoglobulinemia. , 1999, Haematologica.
[58] F. Giostra,et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. , 1994, Journal of hepatology.